上海莱士：SR604注射液新增血管性血友病患者出血发作预防治疗临床试验申请获受理

Core Viewpoint - Shanghai Raist (002252.SZ) has received a notice from the National Medical Products Administration, approving the clinical trial application for the new indication of SR604 injection for the prevention of bleeding episodes in patients with vascular hemophilia [1] Company Summary - The company announced that it has submitted an application for clinical trials of SR604 injection, which is a humanized high-affinity monoclonal antibody that specifically inhibits the anticoagulant function of human activated protein C [1] - As of the date of the announcement, there are no products on the market globally that target the same mechanism as SR604, and no antibody drugs have been approved for the prevention of bleeding in vascular hemophilia [1]